医学
颈动脉内膜切除术
冲程(发动机)
内科学
心脏病学
心肌梗塞
颈动脉疾病
人口
冠状动脉疾病
血运重建
外科
狭窄
机械工程
工程类
环境卫生
作者
Malik Ghannam,Mohammad AlMajali,Farid Khasiyev,Mahmoud Dibas,Abdullah Al Qudah,Fawwaz Almajali,Dana Ghazaleh,Asghar Shah,Fayez H. Fayad,Kareem Joudi,Bashar Zaidat,Chris Childs,Bennett R. Levy,Yasmeen Abouainain,Denise M. D. Özdemir‐van Brunschot,Liqi Shu,Eric Goldstein,Ammad A. Baig,Hannah Roeder,Nils Henninger
出处
期刊:PubMed
日期:2024-04-01
卷期号:55 (4): 921-930
被引量:6
标识
DOI:10.1161/strokeaha.123.044246
摘要
Transcarotid artery revascularization (TCAR) is an interventional therapy for symptomatic internal carotid artery disease. Currently, the utilization of TCAR is contentious due to limited evidence. In this study, we evaluate the safety and efficacy of TCAR in patients with symptomatic internal carotid artery disease compared with carotid endarterectomy (CEA) and carotid artery stenting (CAS). A systematic review was conducted, spanning from January 2000 to February 2023, encompassing studies that used TCAR for the treatment of symptomatic internal carotid artery disease. The primary outcomes included a 30-day stroke or transient ischemic attack, myocardial infarction, and mortality. Secondary outcomes comprised cranial nerve injury and major bleeding. Pooled odds ratios (ORs) for each outcome were calculated to compare TCAR with CEA and CAS. Furthermore, subgroup analyses were performed based on age and degree of stenosis. In addition, a sensitivity analysis was conducted by excluding the vascular quality initiative registry population. A total of 7 studies involving 24 246 patients were analyzed. Within this patient cohort, 4771 individuals underwent TCAR, 12 350 underwent CEA, and 7125 patients underwent CAS. Compared with CAS, TCAR was associated with a similar rate of stroke or transient ischemic attack (OR, 0.77 [95% CI, 0.33-1.82]) and myocardial infarction (OR, 1.29 [95% CI, 0.83-2.01]) but lower mortality (OR, 0.42 [95% CI, 0.22-0.81]). Compared with CEA, TCAR was associated with a higher rate of stroke or transient ischemic attack (OR, 1.26 [95% CI, 1.03-1.54]) but similar rates of myocardial infarction (OR, 0.9 [95% CI, 0.64-1.38]) and mortality (OR, 1.35 [95% CI, 0.87-2.10]). Although CEA has traditionally been considered superior to stenting for symptomatic carotid stenosis, TCAR may have some advantages over CAS. Prospective randomized trials comparing the 3 modalities are needed.